Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
RNS Number : 8347N
FastForward Innovations Limited
26 May 2020
FastForward Innovations Ltd / AIM: FFWD / Sector: Closed End Investments
26 May 2020
FastForward Innovations Ltd ("FastForward" or, "FFWD")
Investee Company Update: EMMAC Life Sciences
FastForward Innovations Ltd, the AIM quoted company focusing on making investments in fast growing and industry leading businesses, is pleased to note the following announcement released today concerning investee company EMMAC Life Sciences ('EMMAC'). FastForward has a 2.3% interest in the issued stock of EMMAC.
The announcement is set out below without material changes or adjustments.
EMMAC Life Sciences Group ('EMMAC' or the 'Group')
EMMAC to manufacture product for COVID-19 clinical trial
Medalchemy, part of Consortium led by University of Valencia, to investigate T12 molecule as treatment for Coronavirus
26 May 2020, London. EMMAC Life Sciences Group, Europe's leading independent cannabis company, is pleased to announce that Medalchemy, the Group's GMP certified manufacturing site in Alicante, Spain, will manufacture product for a clinical trial as part of a Consortium led by the University of Valencia. The clinical trial in COVID-19 patients will use the T12 molecule to prevent disease progression towards Adult Respiratory Distress Syndrome ('ARDS'), which is believed to be the leading cause of death in COVID-19 patients. The T12 molecule targets Goodpasture antigen-binding protein ('GPBP'), an extracellular protein kinase overexpressed in the lung, of COVID-19 patients, which is suspected to enlarge alveolar septum causing poor blood oxygenation in ARDS induced by other pathogens.
With over a decade of experience in the research, development and manufacture of active pharmaceutical ingredients (APIs), Medalchemy is EMMAC's research and development facility in Spain, one of its two GMP-Certified laboratories, in addition to Rokshaw Laboratories, in the UK.
Antonio Costanzo, CEO of EMMAC, said: "We are very pleased that through Medalchemy, our GMP-Certified laboratory in Spain, that we are able to support this urgent initiative. During these unprecedented times it is important Medalchemy is able to offer its wealth of expertise and facilities to support such vitally important advancements for us all."
- Ends -
About EMMAC Life Sciences Group
EMMAC Life Sciences Group is Europe's leading independent cannabis company, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. With a unique supply and distribution network throughout Europe, EMMAC's vision is to bring the life-enhancing potential of cannabis to the people who need it.